Lv4
560 积分 2023-04-11 加入
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial
3小时前
待确认
Pancreatic cancer
1个月前
已完结
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
3个月前
已完结
Obinutuzumab Treatment of Follicular Lymphoma
3个月前
已完结
[Job exposure matrices]
3个月前
已关闭
Occupation and risk of lymphoma: a multicentre prospective cohort study (EPIC)
3个月前
已完结
Polygenic Risk, Agent Orange Exposure, and Lymphoid Neoplasms in the Veterans Affairs Million Veteran Program
4个月前
已完结
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
4个月前
已完结
Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study
4个月前
已完结
Clinical outcome of patients with follicular lymphoma and bulky disease after Rituximab‐CHOP immunochemotherapy with and without consolidating radiotherapy
5个月前
已完结
皖公网安备34019202002308
